Pioneering Founders, Experienced Leadership and World-class Advisors


Dr. Lu has served as our CEO since he co-founded Senti Bio in 2016. Since 2010, Dr. Lu has been an MIT faculty member in the departments of Biological Engineering and Electrical Engineering and Computer Science. In addition, Dr. Lu has been a co-founder and a Scientific Advisory Board member to a number of biotechnology and biopharmaceutical companies, including BiomX, Corvium, Eligo Bioscience, Engine Biosciences, Synlogic and Tango Therapeutics.

Dr. Lu earned his M.D. from Harvard Medical School and his Ph.D. in Electrical and Biomedical Engineering from Massachusetts Institute of Technology as part of the Harvard-MIT Health Sciences and Technology Medical Engineering and Medical Physics Program. Dr. Lu has extensive experience in the field of synthetic biology and has received numerous awards: NIH New Innovator Award, US President Early Career Award for Scientists and Engineers, MIT Technology Review’s TR35, Navy and Army Young Investigator Prizes and others.


Ms. Li has been serving as our interim Chief Financial Officer and Treasurer since May 2024. She is a seasoned finance executive with more than 25 years of extensive experience in equity financing, strategic financial planning and analysis, technical accounting, and internal controls. Prior to joining Senti, from 2019 to 2023, she held several roles at Nkarta Therapeutics, a publicly held biopharmaceutical company, including most recently as Chief Administrative Officer. She oversaw Nkarta’s accounting, finance, and associated budgetary and administrative operations, SEC regulatory compliance, and human resources administration. Before that, she was Senior Vice President of Finance at Amunix, a private biotech company acquired by Sanofi. Over her 12-year career at OncoMed Pharmaceuticals, she held senior leadership roles in finance, accounting and operations, including most recently as Principal Financial and Accounting Officer. Her contributions were pivotal in guiding the company through its IPO and a cross-border merger, and she played a key role in major strategic partnership transactions.

Ms. Li is a Certified Public Accountant (inactive) and member of the American Institute of Certified Public Accountants. She earned her BA from the National Taiwan Normal University and MBA from San Francisco State University.


Dr. Rajangam is responsible for leading the development and regulatory strategy to rapidly advance Senti Bio’s off-the-shelf CAR-NK cell oncology programs into and through clinical development. Dr. Rajangam served in leadership roles at various biotech companies, most recently Nkarta Therapeutics where, as chief medical officer, she was responsible for clinical development of CAR-NK cell therapies for oncology. Prior to Nkarta, she was chief medical officer at Atara Biotherapeutics where she led the development of T-cell therapies for oncology, neurology and infectious diseases. Prior to that, Dr. Rajangam was chief medical officer of Cleave Biosciences, where she led oncology clinical development programs. Prior to becoming a chief medical officer, Dr. Rajangam gained relevant senior leadership experience at Onyx and Exelixis, while contributing to the clinical development and global approval of several marketed oncology products including Kyprolis®, Cotellic® and Cometriq®/Cabometyx®. Dr. Rajangam currently serves on the board of directors of Turnstone Biologics, a clinical-stage biotechnology company developing next-generation tumor infiltrating lymphocyte cell therapies and oncolytic virus cancer immunotherapies.

Dr. Rajangam received a medical degree from St. Johns’ Medical College and completed her surgical residency with a focus on oncology at the Postgraduate Institute of Medical Education and Research (PGIMER), both in India. She received a Ph.D. in biomedical cell and tissue engineering from Northwestern University.


Mr. Rhee has been overseeing Senti Bio’s legal function since joining Senti Bio in 2021.  He brings over 20 years of legal and compliance experience working at global public and private companies. Prior to joining Senti Bio, Mr. Rhee served as Vice-President, Legal, at Sangamo Therapeutics, Inc., a biotechnology company developing genomic medicine. Prior to Sangamo, Mr. Rhee held positions at the University of California, San Francisco and Bio-Rad Laboratories, Inc. Prior to going in-house, Mr. Rhee practiced intellectual property law at Dewey Ballantine LLP. Mr. Rhee began his career as a Patent Examiner at the United States Patent and Trademark Office. In these positions, Mr. Rhee built his expertise in a number of practice areas, including intellectual property, litigation, transactions, M&A, compliance, and corporate governance.

Mr. Rhee received a B.S. in Chemical Engineering and Biology and a J.D. from the University of Virginia.


Mrs. Alford has been leading Senti’s R&D and clinical operations since 2022. She brings over 20 years of clinical operations experience, including departmental build outs and trial progression from First in Human/Phase I to registration. Prior to joining Senti, Mrs. Alford held various clinical roles at Kronos Bio, Peloton Therapeutics (acquired by Merck), and Reata Pharmaceuticals. She was also a clinical research consultant advising a number of companies on clinical development, strategy, and operations.  Mrs. Alford was part of the clinical teams for several FDA-approved products, including WELIREG® for the treatment of von Hippel-Lindau (VHL)-associated renal cell carcinoma.

Mrs. Alford earned a master’s degree in Clinical, Counseling and Applied Psychology from Northwestern University, and a bachelor’s degree in Biology & Psychology from Rhodes College.


Mr. Chen joined Senti Bio in 2023 and leads the CMC / Technical Operations department and is responsible for the process development, analytical development, and manufacturing activities.  He brings over 30 years of experience in the biopharma industry in the development and manufacturing of proteins, enzymes, monoclonal antibodies, gene and cell therapy products.  Prior to Senti Bio, Mr. Chen was Vice President of Manufacturing at Grace Science and led the CMC activities for the development and manufacturing of a gene therapy for an ultra rare disease indication. Prior to that, he was the head of External Manufacturing at Sangamo Therapeutics and was responsible for GMP manufacturing and supply of plasmids, mRNA, viral vectors and cell therapy products including stem cells and Treg cells. Mr. Chen has had increasing roles of responsibility and has been in involved in the initial process development and manufacturing of Humira®, the design of a large-scale biologics manufacturing facility for Amgen Rhode Island to manufacture Enbrel®, led the CMC project management department at Chiron and was the CMC and tech transfer leader at Genentech for various products including Activase®, Rituxan® and Perjeta®.

Mr. Chen received his Chemical Engineering degree from UCLA and his MBA from the Babson FW Olin Graduate School of Business.


Mrs. Dragon is responsible for all facets of Senti’s people strategy, with DE&I, Empathy and Collaboration as key building blocks in designing Senti’s employee experience using a People-Centered approach. Prior to her role at Senti, she was Assistant Vice President with Aon’s Health Solutions Practice where she helped clients develop people attraction and retention strategies, and implemented multiple new employee programs. Prior to that, she worked globally for Mercer Human Resource Consulting, The Los Angeles Times, and Willis Towers Watson.

Mrs. Dragon received her B.F.A. Degree in Electronic Media Communications from The University of Cincinnati.


Ms. Thacker joined Senti in 2022 with over 20 years of leadership experience in regulatory affairs and quality assurance in the biopharmaceutical industry, ushering many novel biotherapeutics into First-in-Human clinical trials through development and approval in the US and internationally. Prior to joining Senti, she served as VP and Head of Quality and Regulatory at Harpoon Therapeutics providing regulatory and compliance oversight of their ongoing preclinical and clinical development of their suite of T cell engagers and, prior to that, as VP of Regulatory Affairs at Gritstone Bio where she built out the Regulatory Affairs function and provided regulatory strategic expertise on the development of personalized therapeutic cancer vaccines, bispecific antibodies, biomarkers, and companion diagnostics. She has also led FDA interactions on the design and quality systems, GMP bioinformatics, and manufacturing facilities. Prior to Gritstone, she served as Senior Director, Head of Regulatory Development, Global Regulatory Affairs at Puma Biotechnology. She has also held positions of increasing responsibility in regulatory Affairs and Quality at Gilead Sciences, Sunesis Pharmaceuticals, Genitope Corporation, Chiron Corporation, and Sanofi Pasteur, supporting numerous clinical development programs, product approvals, launches, and post-marketing support.

Ms. Thacker received a BSc (hons) and MSc from the University of Manitoba in Canada.